Skip to content
Study details
Enrolling now

Study of SGR-1505 in Mature B-Cell Neoplasms

Schrödinger, Inc.
NCT IDNCT05544019ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

52

Study length

about 3 years

Ages

18+

Locations

16 sites in AZ, DE, FL +10

About this study

This trial is testing a treatment called SGR-1505 for people with certain types of mature B-cell cancers. The goal is to see if the treatment is safe and how well it works, as well as find the highest dose that can be given safely.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take SGR-1505
PhasePhase 1
Primary goalNature and number of incidences of dose limiting toxicity (DLT)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Nature and number of incidences of dose limiting toxicity (DLT)., Nature, severity, and number of incidences of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation.

Secondary: Disease Control Rate, Duration of Response (DOR), Objective Response Rate (ORR), SGR-1505 Area Under the Concentration Versus Time Curve (AUC), SGR-1505 Maximal Plasma Concentration (Cmax), SGR-1505 Time to Maximal Plasma Concentration (tmax)

Body systems

Oncology